| |
Univariate analysis
|
Multivariate analysis
|
|---|
|
Odds ratio (95% CI)
|
P value
|
Odds ratio (95% CI)
|
P value
|
|---|
|
Age
|
0.99 (0.95–1.02)
|
0.41
| | |
|
RA duration
|
1.00 (0.99–1.00)
|
0.37
| | |
|
MTX dose
|
1.07 (0.94–1.238)
|
0.30
| | |
|
DAS28(ESR)
|
0.50 (0.31–0.75)
|
<0.001
|
0.67 (0.40–1.06)
|
0.09
|
|
HAQ-DI
|
0.69 (0.36–1.29)
|
0.25
| | |
|
EQ-5D
|
41.89 (1.88–1496.64)
|
0.02
|
1.66 (0.01–287.19)
|
0.83
|
|
CRP
|
0.88 (0.73–1.03)
|
0.12
| | |
|
RF
|
1.00 (0.99–1.00)
|
0.50
| | |
|
ACPA
|
1.00 (0.99–1.00)
|
0.30
| | |
|
MMP-3
|
1.00 (0.99–1.00)
|
0.69
| | |
|
TNFα
|
1.18 (0.98–1.72)
|
0.09
| | |
|
IL-6
|
1.00 (0.99–1.01)
|
0.46
| | |
|
HAQ-DI at 24 h
|
0.53 (0.25–1.04)
|
0.07
| | |
|
EQ-5D at 24 h
|
123.61 (4.82–5356.39)
|
<0.001
|
26.33 (0.514–7838.05)
|
0.09
|
|
CRP at 24 h
|
0.85 (0.66–1.02)
|
0.08
| | |
|
CRP at 48 h
|
0.77 (0.53–1.02)
|
0.07
| | |
|
TNFα at 24 h
|
0.20 (0.05–0.55)
|
<0.001
|
0.01 (0.04e−2–0.22)
|
<0.01
|
|
TNFα at 48 h
|
0.01 (2.636e-5–0.54)
|
<0.001
|
9.26 (0.30–342.47)
|
0.20
|
|
IL-6 at 24 h
|
0.98 (0.95–0.99)
|
0.03
|
1.00 (0.97–1.01)
|
0.92
|
|
IL-6 at 48 h
|
0.04 (0.01–0.60)
|
0.02
|
0.97 (0.92–1.03)
|
0.27
|
|
CZP at 24 h
|
15.56 (1.95–154.84)
|
<0.001
|
1.00 (0.99–1.01)
|
0.33
|
|
CZP at 48 h
|
16.76 (1.82–190.40)
|
0.01
|
1.00 (0.99–1.01)
|
0.24
|
- RA rheumatoid arthritis, MTX methotrexate, DAS disease activity score, HAQ-DI health assessment questionnaire disability index, EQ-5D EuroQol 5 Dimension, CRP C-reactive protein, RF rheumatoid factor, ACPA anti-cyclic citrullinated peptide antibody, MMP-3 matrix metalloproteinase 3, TNFα tumor necrosis factor, IL-6 interleukin-6, CZP cerolizumab pegol
